CytoMed Therapeutics Limited (GDTC) Gamma Exposure (GEX) & Greeks

Gamma exposure (GEX) analysis shows how options positioning creates dealer hedging pressure across strikes. Includes delta, vanna, charm, vomma, and vega exposure by strike price.

CytoMed Therapeutics Limited (GDTC) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $14.2M, listed on NASDAQ, employing roughly 43 people, carrying a beta of -0.17 to the broader market. CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. Led by Chee Kong Choo, public since 2023-04-14.

Greeks exposure analysis shows dealer hedging pressure across strike prices for all six Greeks. No recent options activity for GDTC as of 2026-06-01; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.

Learn how gamma exposure is reported and how to read the data →